Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...

Johnson & Johnson's Tecvayli has been approved as part of a combination regimen with its Genmab-partnered Darzalex Faspro as a second-line therapy for relapsed or refractory multiple myeloma, just 55 ...

Objective Heart failure (HF) is a major public health issue due to its high morbidity, mortality and healthcare burden. This ...

Introduction In aortic valve disease, several interventions are available. In young people who are still growing, or ...